NLRP3 maintains healthy pericytes in the brain
Abstract Background Pericytes regulate structure and function of cerebral capillaries. Growing evidence shows that pericytes are damaged in the brain of Alzheimer’s disease (AD), which potentially contributes to AD pathogenesis. NLRP3-contained inflammasome is activated in AD brain and considered as a promising target for therapy. However, how NLRP3 affects brain pericytes is unclear. In our study, we investigated physiological function of NLRP3 in pericytes. Methods Immunohistological methods and Western blot were used to investigate pericytes and vasculature in the brains of 9-month-old NLRP3-deficient and wild-type littermate mice. Pericytes were also cultured and treated with NLRP3 inhibitor, recombinant IL-1β and AKT inhibitor. Then, proliferation, apoptosis and expression of PDGFRβ and CD13 in pericytes were analysed with biochemical methods. To investigate underlying molecular mechanisms, phosphorylation of protein kinases such as AKT, ERK and NF- k B were quantified. Results We observed that NLRP3 deficiency reduced the coverage of PDGFRβ-positive pericytes and collagen type IV-immunereactive vasculature in the brain. NLRP3 deficiency was also shown to decrease PDGFRβ and CD13 proteins in isolated cerebral microvessels. In cultured pericytes, inhibition of NLRP3 with MCC950 attenuated cell proliferation but did not induce apoptosis. NLRP3 inhibition also decreased protein levels of PDGFRβ and CD13. On the contrary, treatments with IL-1β increased protein levels of PDGFRβ and CD13 in pericytes. The alteration of PDGFRβ and CD13 protein levels was correlated with phosphorylation of AKT. Inhibition of AKT reduced PDGFRβ and CD13 in cultured pericytes. Conclusions NLRP3 might be essential to maintain healthy pericytes in the brain through activating AKT. Adverse effects on brain pericytes should be considered in the possible clinical therapies with NLRP3 inhibitors.